PT  - JOURNAL ARTICLE
AU  - Summers, Jaye
ED  - Liu-Seifert, Hong
TI  - EXPEDITION EXT
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 15--17
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/15.short
4100  - http://mdc.sagepub.com/content/15/9/15.full
AB  - Patients with mild Alzheimer’s disease enrolled in EXPEDITION EXT had already received 80 weeks of treatment with either solanezumab or placebo. Utilizing a unique approach to the delayed-start model, researchers report that cognitive and instrumental function outcomes in delayed-start patients did not catch up to those in early-start patients, supporting the benefit of initiating treatment as early as possible.